http://orcid.org/0000-0002-6439-3865
References
- Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci. 2007;261:127–133.
- Van Berkel MA, Twilla JD, England BS. Emergency department management of a myasthenia gravis patient with community-acquired pneumonia: does initial antibiotic choice lead to cure or crisis? J Emerg Med. 2016;50(2):281–285.
- Bershad EM, Feen ES, Suarex JI. Myasthenia gravis crisis. South Med J. 2008;101:63–69.
- Argov Z, Brenner T, Abramsky O. Ampicillin may aggravate clinical and experimental myasthenia gravis. Arch Neurol. 1986;43:255–256.
- Changqin L, Fang H. Investigation on the mechanism of exacerbation of myasthenia gravis by aminoglycoside antibiotics in mouse model. J Huazhong Univ Sci Technol. 2005;25(3):294–296.
- Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol. 2007;14:617–620.
- Suzuki S, Utsugisawa K, Nagane Y, et al. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis. 2011;740583.
- Romi F, Skeie GO, Gilhus EN, et al. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol. 2005 Mar;62(3):442–446.
- Suzuki S, Satoh T, Yasuoka H, et al. Novel autoantibodies to a voltage-gated potassium channel KV1.4 in a severe form of myasthenia gravis. J Neuroimmunol. 2005;170(1):141–149.